_edited.png)
New Tinnitus Guidelines 2026: What UK Patients Should Know
New tinnitus guidelines were published in the USA in October 2026. As an audiologist, I have read them closely: here is what is new, what it means for tinnitus treatment in the UK, and how it compares with the NICE and British Society of Audiology guidance we follow here.
If you live with ringing, buzzing or hissing in your ears, you have probably come across a lot of conflicting advice about tinnitus treatment. So when a major new guideline is published, I think it is worth explaining what it says in plain English. On 12 October 2026, the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF) published its updated Clinical Practice Guideline: Tinnitus. It replaces the American guideline from 2014 and is now the most up-to-date major review of tinnitus care.
Here in the UK, my tinnitus assessments and management plans are guided by two documents: the NICE guideline NG155, published in 2020, and the British Society of Audiology (BSA) Practice Guidance: Tinnitus in Adults, published in 2021. Both are now a few years old, and the BSA guidance was due for review this month.
So does the new American guideline change anything for you? In short, it confirms much of what good UK tinnitus care already looks like, and adds a few new and genuinely interesting ideas that I want my patients to know about.
What evidence are the new guidelines based on?
A clinical guideline isn't based on one study. It's a structured review of the best available research, weighed up by a panel of clinicians and patient representatives.
For this update, the panel revisited the 2014 guideline and reviewed the research published since, giving most weight to systematic reviews and randomised controlled trials, the most reliable kinds of evidence. They then balanced the quality of that evidence against the likely benefits, harms and costs of each approach, and patients' preferences.
Each of the 16 recommendations is graded by how strong the evidence is:
Strong recommendation: good-quality evidence, and the benefits clearly outweigh the harms. Three statements are graded this way: telling bothersome from non-bothersome tinnitus, asking about self-harm, and avoiding routine scans.
Recommendation: the benefits outweigh the harms, but the evidence is less complete. This covers most of the core care: a hearing assessment, education, hearing aids, cochlear implant referral, CBT and measuring outcomes.
Option: the evidence is weaker or mixed, so the choice depends on the individual. Bimodal neuromodulation sits here.
The guideline also includes three recommendations against: medication, dietary supplements and rTMS for treating tinnitus itself.
One detail I find telling: the guideline excludes people whose tinnitus has an identifiable cause other than hearing loss. The panel explains that these patients are left out of nearly all randomised trials of tinnitus treatment, so the results can't be reliably applied to them. It is a good reminder that tinnitus research mainly reflects tinnitus linked to hearing loss, and that pulsatile tinnitus needs its own medical assessment.
Where the evidence ran out, the panel listed what research is still needed. Because it draws on research from the six years since NICE published its guidance, such as the recent trials of neuromodulation devices, the US guideline can say things that NICE could not in 2020.
What the new 2026 US tinnitus guidelines say
The updated guideline was written by a wide panel, including ENT surgeons, audiologists, a psychiatrist, a neurologist, a radiologist and a patient advocate. It has been endorsed by the American Academy of Audiology, the American Speech-Language-Hearing Association and the American Tinnitus Association. It focuses on adults whose tinnitus has lasted six months or more and affects their quality of life, and it sets out 16 key action statements for clinicians.
The headline message is one I share with my patients every week: there is no single cure, but there is a lot that genuinely helps, and the right plan depends on you.
What the guideline recommends
A proper hearing assessment for everyone with tinnitus. A comprehensive audiological evaluation is now recommended for all patients, not just some. Most tinnitus sits alongside some degree of hearing loss, often undiagnosed.
Separating bothersome from non-bothersome tinnitus. This is a strong recommendation. Many people notice tinnitus without being troubled by it, and they mainly need reassurance and information.
Asking about self-harm. Clinicians should ask people with bothersome tinnitus about their risk of self-harm. This is a strong recommendation. Tinnitus can take a real toll on mental health, and this new statement recognises that.
Education and counselling about what tinnitus is, what affects it and how it is managed.
Hearing aid evaluation for anyone with bothersome tinnitus and hearing difficulties.
Cochlear implant referral for people whose hearing loss meets the criteria. This is new.
Cognitive behavioural therapy (CBT). CBT is recommended. It does not remove the sound, but it has the best evidence for reducing the distress tinnitus causes.
Follow-up to check whether treatment is working.
What it lists as options
Sound enrichment. What used to be called "sound therapy" has been renamed sound enrichment to better describe it: using background sound to make tinnitus less noticeable.
Asking about somatosensory tinnitus. This is tinnitus that changes when you move or clench your jaw, head or neck. It is new to the guideline.
Bimodal neuromodulation. This is the most novel addition. These devices pair sound through headphones with gentle electrical stimulation, usually of the tongue. The guideline says clinicians may offer it, while calling for more independent, long-term research.
What it advises against
Routine scans. Brain or inner-ear imaging is strongly advised against unless there are specific concerning features.
Medication, dietary supplements and rTMS. The guideline advises against routinely using drugs, supplements or repetitive transcranial magnetic stimulation (a magnetic brain stimulation treatment) to treat tinnitus itself.
What changed since 2014
The update adds five new statements: self-harm, somatosensory tinnitus, cochlear implants, bimodal neuromodulation and follow-up. It also drops the old split between "primary" and "secondary" tinnitus and adds a new flowchart for clinicians.
The UK tinnitus guidelines: NICE and the BSA
NICE guideline NG155 (2020)
The NICE tinnitus guideline covers adults and children across GP surgeries, community services and hospitals. Its recommendations were developed before the COVID-19 pandemic. Key points:
Reassurance from the first appointment: tinnitus is common, may settle by itself, is rarely linked to a serious physical problem, and there are many ways to live well with it.
An audiological assessment for everyone with tinnitus, plus tympanometry if a middle-ear problem is suspected.
Questionnaires such as the Tinnitus Functional Index to measure impact, and screening for sleep problems.
No pitch or loudness matching tests, which NICE judged unhelpful.
Targeted scanning: an MRI for one-sided tinnitus or tinnitus with other warning signs, imaging for pulsatile tinnitus, and no scan for tinnitus in both ears with no other symptoms.
Hearing aids offered where hearing loss affects communication, considered where it does not, and not offered if hearing is normal.
Psychological support in steps: digital tinnitus-specific CBT first, then group therapy, then one-to-one CBT.
Do not offer betahistine for tinnitus.
No recommendation either way on sound therapy, combined therapies or neuromodulation, because the evidence was too weak. NICE asked for more research instead.
BSA Practice Guidance: Tinnitus in Adults (2021)
The BSA guidance is the hands-on manual for audiologists. It builds on NICE and goes into much more practical detail:
A minimum test battery: otoscopy, a hearing test including 3 kHz and 6 kHz, and tympanometry where needed.
Tests to avoid: pitch and loudness matching, and loud-sound tests that can aggravate tinnitus.
The Tinnitus Functional Index to measure progress, with an improvement of 18 points or more counting as meaningful for UK patients.
Sound enrichment at a level just below the tinnitus, rather than masking it completely.
Hearing aids are widely supported by clinicians, even though high-quality trial evidence was limited at the time.
CBT described as the only tinnitus treatment backed by a high-quality clinical trial.
Cochlear implants are not for tinnitus alone, but tinnitus can strengthen the case when severe hearing loss is present.
Not recommended: drugs for tinnitus itself, supplements such as ginkgo biloba, zinc, melatonin and magnesium, and ear candles, which can damage the ear.
Neuromodulation (rTMS, vagus nerve stimulation and similar) treated as experimental.
A written tinnitus individual management plan agreed with each patient.
US vs UK tinnitus guidelines at a glance
Topic | US AAO-HNSF (2026) | NICE NG155 (2020) | BSA guidance (2021) |
Hearing assessment | Recommended for everyone | Offered to everyone | Minimum test battery for everyone |
Mental health and self-harm | Ask about self-harm risk (new) | Urgent crisis referral if high suicide risk | Assess distress and suicide risk |
Scans (MRI/CT) | Not routinely; only with concerning features | Only for one-sided, pulsatile or with other signs | Consider for one-sided tinnitus or uneven hearing loss |
Hearing aids | Evaluation if hearing difficulty | Offer if hearing loss affects communication | Supported in clinical practice |
Sound enrichment | Option | No recommendation (research needed) | Option, set just below tinnitus level |
CBT | Recommended | Stepped: digital, group, then individual | Best-evidenced treatment |
Cochlear implants | Refer if criteria met (new) | Not addressed | Not for tinnitus alone |
Medication | Not routinely | No betahistine | No drug for tinnitus itself |
Supplements | Not recommended | Not addressed | Not recommended |
rTMS | Not recommended | No recommendation (research needed) | Experimental |
Bimodal neuromodulation | Option (new) | No recommendation (research needed) | Experimental |
Somatosensory tinnitus | Option to ask about (new) | Not addressed | Ask in history; check jaw and neck |
My take: what's new, and what it means for UK tinnitus care
Where everyone agrees
Reading the three side by side, I'm struck by how much they agree. Every guideline starts with a proper hearing assessment. Every one puts CBT at the heart of managing tinnitus distress. And every one steers people away from tablets and supplements sold as tinnitus cures. If you have spent money on ginkgo biloba or magnesium with little to show for it, you are not alone, and the evidence backs up your experience.
They also agree that most people do not need a scan. Imaging is for specific warning signs, such as tinnitus in one ear only, pulsing tinnitus, or sudden changes in hearing.
What's genuinely new
Bimodal neuromodulation gets a cautious green light. This is the most interesting change. The US guideline now lists sound-plus-tongue-stimulation devices as an option, while UK guidance still treats neuromodulation as experimental. It is the newest idea in this guideline, but in my view also the one with the weakest evidence behind it (more on this below).
Cochlear implants enter the tinnitus conversation. For people with severe or profound hearing loss, a cochlear implant can help with tinnitus as well as hearing. The US guideline now says these patients should be referred for assessment.
Somatosensory tinnitus is recognised. If your tinnitus changes when you clench your jaw or move your neck, that is a useful clue. It can point towards jaw or neck factors worth exploring.
Mental health is front and centre. Asking about self-harm is now a formal step in the US. UK guidance already covers this, and I think it is right that it is said plainly.
"Sound therapy" becomes "sound enrichment". It is a small change in wording, but it matches how UK audiologists already use sound: gently, below the level of the tinnitus, rather than trying to drown it out.
A closer look at bimodal neuromodulation (Lenire)
I want to be clear about why the US recommendation on bimodal neuromodulation is only a cautious "option". The main device, Lenire, has been tested in a series of clinical trials known as TENT-A1, TENT-A2 and TENT-A3. All three were commissioned by the manufacturer, Neuromod Devices.
In my view, those studies have important design weaknesses:
No proper placebo control. The trials compared different device settings, or compared sound-only stimulation with sound plus tongue stimulation in the same people one after the other. The latest trial, TENT-A3, gave everyone six weeks of sound-only stimulation followed by six weeks of the full treatment. None compared the device with a sham device or a well-established treatment such as CBT.
Industry funding. When the company that sells a device also funds and designs its trials, independent replication matters even more.
Mixed results. Many participants improved, but not all did, and some people's symptoms worsened before they improved.
The US guideline recognises this: it calls for independent studies of the long-term, real-world effect, and for research into how much the tongue stimulation adds compared with the sound alone. The NICE and BSA guidelines largely pre-date these trials, which is why they treat neuromodulation as experimental.
What we need now are independent randomised controlled trials with proper control groups. Until then, I would encourage anyone considering bimodal neuromodulation to weigh the cost carefully, keep their expectations realistic, and try the treatments with the strongest evidence first: a hearing assessment, hearing aids where needed, sound enrichment and CBT. For these reasons, I don't currently offer Lenire at Ear Care Specialists. I'll keep reviewing that decision as independent evidence emerges.
Where the UK guidance is ahead or different
NICE gives clearer referral timescales and a stepped route into CBT, starting with digital programmes. The BSA guidance offers practical detail on which questionnaires to use, which tests to avoid, and how to agree a written management plan. The American guideline does not replace these. It adds to them.
The gap is that NICE made no recommendation on sound therapy or neuromodulation in 2020, simply because the evidence was not there yet. With the BSA guidance now due for review, I expect UK advice to catch up on some of these newer areas.
What this means if you have tinnitus
On both sides of the Atlantic, the advice for anyone troubled by tinnitus comes down to a few clear steps:
Get your hearing properly tested. Treating an underlying hearing loss is often the single most helpful thing we can do.
Understand your tinnitus. Good information takes away a lot of the fear, and fear is what keeps tinnitus loud in your mind.
Use sound to your advantage. Gentle background sound, especially at night, can make tinnitus far less intrusive.
Consider CBT-based support if tinnitus is affecting your mood, sleep or concentration.
Be wary of quick fixes. Supplements and unproven devices are expensive, and the evidence does not support them.
Keep reviewing your progress with your clinician, so your plan changes as you do.
When to seek help urgently
Most tinnitus is not an emergency, but one situation is. Go to A&E the same day if you notice sudden hearing loss in one or both ears. This may or may not be accompanied by tinnitus. This can be sudden sensorineural hearing loss and NICE advises it is seen within 24 hours, because early steroid treatment gives the best chance of recovery.
See your GP promptly, and ask about a referral, if your tinnitus comes with:
a pulsing sound in time with your heartbeat (pulsatile tinnitus)
tinnitus in one ear only, or hearing that is worse on one side
dizziness or vertigo
tinnitus that started after a head injury
distress that is affecting your sleep, mood or daily life
If you are having thoughts of harming yourself, please talk to your GP, call NHS 111, or call Samaritans free on 116 123, any time.
How we can help at Ear Care Specialists
I'm Dr Jeff Davies, an independent audiologist at Ear Care Specialists in Nottingham. I hold a PhD in tinnitus and hearing loss, and I have lived with tinnitus myself since early childhood, so I know first-hand how it feels. My tinnitus care follows the NICE and BSA guidance, and I keep a close eye on new evidence like the 2026 US guideline. A tinnitus appointment with me includes a thorough history, otoscopy, tympanometry (if appropriate), audiometry, assessment of your tinnitus with questionnaires and above all, an in depth conversation about your tinnitus and it's impacts on life. We formulate a management strategy and discuss possible treatment options.
We also host the free Nottingham Tinnitus Support Group at our clinic on Mansfield Road. Sessions alternate between themed discussions and talks from tinnitus researchers, audiologists and psychotherapists.
If tinnitus is getting in the way of your sleep, work or peace of mind, book a tinnitus assessment in Nottingham or call us on 0115 990 20 82, and let's work out a plan that suits you.
This article is for general information and does not replace a personal assessment by a qualified clinician.
Comments